Iscucin Pini St.D ampoules, 10x1 ml

Information about Iscucin Pini Strength D

Iscucin Pini Starch D is a liquid dilution for injection containing the active ingredient Viscum album (Pini) e planta tota K.This product is available without a prescription.

Areas of application

According to the anthroposophical knowledge of man and nature, Iscucin Pini Strength D is used in adults to stimulate form and integration forces.This serves to dissolve and reintegrate independent growth processes.Areas of application include malignant and benign tumor diseases, defined precancerous lesions, recurrence prevention after tumor operations as well as chronic cross-border diseases such as Crohn's disease or chronic joint diseases.

Contraindications

Iscucin Pini must not be used in cases of known allergy to mistletoe preparations, acute inflammatory or highly febrile diseases, chronic granulomatous diseases, florid autoimmune diseases under immunosuppressive therapy and in hyperthyroidism with tachycardia.

Precautions and warnings

In the case of primary brain and spinal cord tumors or intracranial metastases with a risk of increased intracranial pressure, the preparation should only be administered according to strict indications and under close clinical control.Caution is advised during pregnancy and breastfeeding as the effects of the drug have not been studied.There is no experience with regard to impairment of the ability to drive or use machines.

Interactions

There are no studies available on interactions with other immunomodulating substances.If appropriate preparations are used promptly, careful dosing and monitoring of appropriate immune indicators is recommended.

Dosage and application

The dosage is carried out individually according to the doctor's instructions.The duration of use is not limited and is determined by the doctor, although it can be several years and breaks of increasing length can be taken.

Side effects

At the beginning of therapy, a slight increase in body temperature and local inflammatory reactions at the injection site may occur.If there is a fever over 38°C or major local reactions over 5 cm in diameter, the next injection should only be given after these symptoms have subsided and at a reduced strength or dose.Allergic or allergoid reactions may occur that require discontinuation of the preparation and initiation of medical therapy.Excessive local reactions can be avoided by using a lower strength of the preparation or a smaller amount of the dose.

Content and manufacturer

The contents include 10 ampoules of 1 ml each. The pharmaceutical company and manufacturer is WALA heil GmbH, Dorfstraße 1, 73087 Bad Boll/Eckwälden.